grant
Discovery of fused heterocyclic pyrazine based novel anti-mitotic agents for metastatic melanoma
Organization MIDDLE TENNESSEE STATE UNIVERSITYLocation MURFREESBORO, UNITED STATESPosted 22 Jul 2024Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY2025AdjuvantAntimitotic AgentsAntimitotic DrugsAntimitoticsAnzataxApoptosisApoptosis PathwayAsotaxAssayB-raf-1BRAFBRAF geneBindingBinding SitesBioassayBiological AssayBlood VesselsBreast CancerBristaxolCancer BiologyCancer TreatmentCancer cell lineCancersCell LineCellLineCheckpoint inhibitorChemicalsClinicalClinical TrialsColchicineCombining SiteComplexDNA mutationDataDevelopmentDiseaseDisorderDisseminated Malignant NeoplasmDoseDose LimitingDrug resistanceDrugsExhibitsFeedbackGenerationsGenetic ChangeGenetic defectGenetic mutationHematopoieticHeterograftHeterologous TransplantationHumanImmune checkpoint inhibitorIn VitroInhibition of Cell ProliferationInterdisciplinary ResearchInterdisciplinary StudyLaboratoriesLytotoxicityM PhaseMEKsMalignant Breast NeoplasmMalignant CellMalignant MelanomaMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant Skin NeoplasmMalignant TumorMaximal Tolerated DoseMaximally Tolerated DoseMaximum Tolerated DoseMedicationMelanomaMelanoma CellMelanoma MetastasisMetabolicMetastatic CancerMetastatic Malignant NeoplasmMetastatic MelanomaMicro-tubuleMicrotubular Function InhibitorsMicrotubulesMitosisMitosis Inhibitor AgentsMitosis Inhibitor DrugsMitosis InhibitorsMitosis StageMitoticMitotic Inhibitor AgentsMitotic Inhibitor DrugsMitotic InhibitorsModern ManModificationMolecular InteractionMolecular Modeling Nucleic Acid BiochemistryMolecular Modeling Protein/Amino Acid BiochemistryMolecular ModelsMulti-Drug ResistanceMultidisciplinary CollaborationMultidisciplinary ResearchMultidrug ResistanceMultiple Drug ResistanceMultiple Drug ResistantMutationNegative Control of Cell ProliferationNegative Regulation of Cell ProliferationPaclitaxelPaclitaxel (Taxol)PatientsPharmaceutical PreparationsPolymersPraxelPrognosisProgrammed Cell DeathProliferatingPropertyPublic HealthPyrazinesPyrimidinePyrimidine AntagonistQuinoxalinesRAFB1Reactive SiteRecurrenceRecurrentRecurrent diseaseRelapsed DiseaseResearchResearch TrainingResistanceResistance to Multi-drugResistance to MultidrugResistance to Multiple DrugResistant to Multiple DrugResistant to multi-drugResistant to multidrugResolutionRoentgen RaysRouteSeriesSiteSkin CancerStrains Cell LinesStructureStructure-Activity RelationshipSurvival RateSynthesis ChemistrySynthetic ChemistryTaxolTaxol ATaxol KonzentratTaxotereTestingTherapeuticToxic effectToxicitiesTubulinWorkX-RadiationX-Ray RadiationX-rayXenograftXenograft procedureXenotransplantationXrayanalogangiogenesisanti-cancer therapycancer cellcancer therapycancer-directed therapychemical structure functionclinical efficacycultured cell linecytotoxicitydesigndesigningdevelopmentaldimerdocetaxeldocetaxoldrug resistantdrug-sensitivedrug/agentgenome mutationhemopoieticimmune check point inhibitorimprovedin vivoindexinginhibitorinnovateinnovationinnovativeinsightlead optimizationmalignancymalignant breast tumormalignant skin tumormelanocytemolecular modelingmouse modelmulti-drug resistantmulti-drug resistant cancermultidrug resistantmultidrug resistant cancermurine modelneoplasm/cancerneuron toxicityneuronal toxicityneurotoxicitynew approachesnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeuticsnew therapynew therapy approachesnew treatment approachnew treatment strategynext generation therapeuticsnovelnovel approachesnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel strategiesnovel strategynovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeuticsnovel therapynovel therapy approachpolymerpolymericpolymerizationpyrimidine analogrefractory cancerresistance to Drugresistantresistant cancerresistant to Drugresolutionsresponsescaffoldscaffoldingscreeningscreeningsstructure function relationshipstudent trainingsuccesstaxanetherapeutically effectivetubulin polymerization inhibitortumortumor growthv-raf Murine Sarcoma Viral Oncogene Homolog B1vascularwater solubilityxeno-transplantxeno-transplantation
Description preview
PROJECT SUMMARY/ABSTRACT. Malignant melanoma is known to be the most aggressive and deadliest
form of skin cancer. Prognosis is poor in the advanced metastatic stage with less than 10% rate of survival.
Thus, new therapeutic approaches are needed for the treatment of metastatic melanoma. Tubulin inhibitors such
as paclitaxel, docetaxel, or…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click